Veradermics Incorporated Common Stock
MANEUnited States
3 filed reports · 170 financial concepts · 0 earnings calls · 6 media appearances
Filed reports
3 reports · Dec 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 461 | Mar 2026 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 268 | Dec 2025 |
Financial data
170 concepts · 729 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial161 concepts · 693 facts · Dec 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents8 · Dec 2024 to Jun 2026
- Stockholders equity (US GAAP)8 · Dec 2024 to Jun 2026
- Temporary equity shares subscribed but unissued subscriptions receivable8 · Dec 2024 to Jun 2026
- Common stock par or stated value per share7 · Dec 2024 to Jun 2026
- Common stock shares authorized7 · Dec 2024 to Jun 2026
- Accounts payable current6 · Dec 2024 to Jun 2026
- Accretion amortization of discounts and premiums investments6 · Dec 2024 to Jun 2026
- Accrued bonuses current6 · Dec 2024 to Jun 2026
- Accrued liabilities current6 · Dec 2024 to Jun 2026
- Accrued professional fees current6 · Dec 2024 to Jun 2026
- Accumulated other comprehensive income loss net of tax6 · Dec 2024 to Jun 2026
- Additional paid in capital6 · Dec 2024 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value6 · Dec 2024 to Jun 2026
- Allocated share based compensation expense6 · Dec 2024 to Jun 2026
- Antidilutive securities excluded from computation of earnings per share amount6 · Dec 2024 to Jun 2026
- Assets6 · Dec 2024 to Jun 2026
- Assets current6 · Dec 2024 to Jun 2026
- Assets noncurrent6 · Dec 2024 to Jun 2026
- Available for sale securities debt securities current6 · Dec 2024 to Jun 2026
- Cash and cash equivalents at carrying value6 · Dec 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect6 · Dec 2024 to Jun 2026
- Common stock shares issued6 · Dec 2024 to Jun 2026
- Common stock shares outstanding6 · Dec 2024 to Jun 2026
- Common stock value6 · Dec 2024 to Jun 2026
Segment9 concepts · 36 facts · Dec 2024 to Jun 2026
- Investment income interest6 · Dec 2024 to Jun 2026
- Labor and related expense6 · Dec 2024 to Jun 2026
- Net income loss6 · Dec 2024 to Jun 2026
- Other general and administrative expense6 · Dec 2024 to Jun 2026
- Segment reporting other item amount6 · Dec 2024 to Jun 2026
- Accretion amortization of discounts and premiums investments2 · Dec 2025 to Mar 2026
- Investment income net amortization of discount and premium2 · Jun 2025 to Jun 2026
- Interest expense nonoperating1 · Dec 2024
- Reportable Segment1 · Dec 2024
Segments
36 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 36 facts
- Reportable36 · Dec 2024 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary38 claims from 3 reports · Mar 2026 to Jun 2026
- Management discussion (MD&A) commentary48 claims from 3 reports · Dec 2025 to Jun 2026
- Risk factors80 risks from 1 annual reports · 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
6 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews3 · Dec 2023 to Apr 2025
- Other appearances2 · Feb 2026 to Mar 2026
- Podcasts1 · Jan 2024
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.